Q1 Earnings Forecast for MacroGenics Issued By HC Wainwright

MacroGenics, Inc. (NASDAQ:MGNX) – Investment analysts at HC Wainwright lifted their Q1 2025 earnings estimates for MacroGenics in a report issued on Tuesday, March 25th. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will post earnings of ($0.69) per share for the quarter, up from their previous estimate of ($0.70). HC Wainwright has a “Neutral” rating and a $2.00 price target on the stock. The consensus estimate for MacroGenics’ current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for MacroGenics’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.89) EPS.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The business had revenue of $49.40 million during the quarter, compared to the consensus estimate of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%.

Separately, StockNews.com cut MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.38.

MacroGenics Trading Down 14.9 %

MGNX opened at $1.26 on Thursday. The stock has a 50-day moving average of $2.51 and a 200 day moving average of $3.16. MacroGenics has a 12 month low of $1.26 and a 12 month high of $19.54. The firm has a market cap of $79.49 million, a P/E ratio of -0.80 and a beta of 2.12.

Institutional Investors Weigh In On MacroGenics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP boosted its holdings in MacroGenics by 5.4% during the 4th quarter. Wellington Management Group LLP now owns 323,857 shares of the biopharmaceutical company’s stock valued at $1,053,000 after acquiring an additional 16,717 shares during the period. Frazier Life Sciences Management L.P. lifted its position in shares of MacroGenics by 5.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,175,665 shares of the biopharmaceutical company’s stock worth $10,321,000 after purchasing an additional 164,938 shares during the last quarter. Two Sigma Advisers LP boosted its stake in shares of MacroGenics by 7.1% during the fourth quarter. Two Sigma Advisers LP now owns 1,118,600 shares of the biopharmaceutical company’s stock valued at $3,635,000 after purchasing an additional 74,596 shares during the period. ProShare Advisors LLC grew its holdings in shares of MacroGenics by 32.4% in the fourth quarter. ProShare Advisors LLC now owns 20,284 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 4,963 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in MacroGenics in the 4th quarter worth about $32,000. 96.89% of the stock is currently owned by hedge funds and other institutional investors.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.